The prefrontal cortex (PFC) has emerged as one of the regions most consistently impaired in
major depressive disorder (MDD). Although functional and structural PFC abnormalities …

Major depressive disorder (MDD) was previously hypothesized to be a disease of
monoamine deficiency in which low levels of monoamines in the synaptic cleft were …

Volumetric reductions in the hippocampus and medial prefrontal cortex (mPFC) are among
the most well-documented neural abnormalities in major depressive disorder (MDD) …

The present paper reviews astrocyte pathology in major depressive disorder (MDD) and
proposes that reductions in astrocytes and related markers are key features in the pathology …

Highlights•Dysfunctional reward processing is central to the pathophysiology of depression.•
Behavioral impairments in depression vary across reward sub-processes.•A distributed …

Alcohol use disorder (AUD) is a widespread disease with limited treatment options.
Targeting the neuroimmune system is a new avenue for developing or repurposing effective …

Animal behavior was classically considered to be determined exclusively by neuronal
activity, whereas surrounding glial cells such as astrocytes played only supportive roles …

Ketamine, a non-competitive antagonist of N-methyl-D-aspartate (NMDA) receptor, displays
a fast antidepressant activity in treatment-resistant depression and in rodent models of …

Anhedonia—which is defined as diminished pleasure from, or interest in, previously
rewarding activities—is one of two cardinal symptoms of a major depressive episode …

Depression is a chronic, recurring, and serious mood disorder that afflicts up to 20% of the
global population. The monoamine hypothesis has dominated our understanding of the …